Condition
Breast Cancer With Low to Intermediate HER2 Expression
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07389200Not Yet Recruiting
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer
NCT07331506Recruiting
Validation of the Oncoliq Test for the Early Detection of Breast Cancer.
NCT01479244Phase 3CompletedPrimary
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Showing all 3 trials